SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GOMEZ JOHN

(Last)

(First)

(Middle)

222 MERCHANDISE MART PLAZA

SUITE 2024

(Street)

CHICAGO

60654

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. [ MDRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Pre, Product Strategy & Dev

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2010

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/24/2010		A		76,500	A	⁽¹⁾	76,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to buy	$11.05	08/24/2010		A		36,000		08/24/2010	08/11/2013	Common Stock	36,000	⁽²⁾	36,000	D
Option to buy	$9.96	08/24/2010		A		60,000		08/24/2010	10/22/2013	Common Stock	60,000	⁽³⁾	60,000	D
Option to buy	$11.13	08/24/2010		A		144,000		08/24/2010	02/04/2014	Common Stock	144,000	⁽⁴⁾	144,000	D
Option to buy	$16.42	08/24/2010		A		168,000		08/24/2010	12/01/2014	Common Stock	168,000	⁽⁵⁾	168,000	D
Option to buy	$18.39	08/24/2010		A		42,000		⁽⁶⁾	03/04/2015	Common Stock	42,000	⁽⁷⁾	42,000	D
Option to buy	$6.64	08/24/2010		A		126,000		⁽⁸⁾	02/27/2016	Common Stock	126,000	⁽⁹⁾	126,000	D
Performance Stock Units⁽¹⁰⁾	$0.00	08/24/2010		A		60,000⁽¹¹⁾		⁽¹⁰⁾	03/15/2013	Common stock	60,000⁽¹¹⁾	⁽¹²⁾	60,000⁽¹¹⁾	D

Explanation of Responses:

1. Received pursuant to the Agreement and Plan of Merger, dated as of June 9, 2010, among Allscripts-Misys Healthcare Solutions, Inc. (which has changed its name to Allscripts Healthcare Solutions, Inc.) ("Allscripts"), Arsenal Merger Corp. and Eclipsys Corporation (the "Merger Agreement") in exchange for 63,750 shares held directly. On the effective date of the merger, the closing price of Allscripts Healthcare Solutions, Inc. common stock was $17.47 per share.

2. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 30,000 shares of Eclipsys Corporation common stock for $13.26 per share.

3. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 50,000 shares of Eclipsys Corporation common stock for $11.95 per share.

4. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 120,000 shares of Eclipsys Corporation common stock for $13.35 per share.

5. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 140,000 shares of Eclipsys Corporation common stock for $19.70 per share.

6. The option may be exercised only to the extent vested. The option is vested with respect to 60.4167% of the underlying shares, and vests with respect to the remaining 39.5833% in 19 equal monthly installments over the nineteen-month period ending March 4, 2012.

7. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 35,000 shares of Eclipsys Corporation common stock for $22.07 per share.

8. The option may be exercised only to the extent vested. The option is vested with respect to 35.4167% of the underlying shares, and vests with respect to the remaining 64.5833% in 31 equal monthly installments over the thirty-one-month period ending February 27, 2013.

9. Received pursuant to the Merger Agreement in exchange for a stock option to acquire 105,000 shares of Eclipsys Corporation common stock for $7.97 per share.

10. Each Performance Stock Unit ("PSU") represents a contingent right to receive a number of shares of Allscripts common stock ranging from zero to 2.7, depending upon Eclipsys' total shareholder return ("TSR") compared to the TSRs of a group of pre-selected companies in the healthcare technology and software industries over a performance period commencing on March 15, 2010 ending on August 24, 2010, the effective date of the merger.

11. Assumes Eclipsys' TSR was at the 50th percentile of the comparison group. Actual payout for PSUs can range from 0% to 270% of the amount shown depending upon relative TSRs for the performance period.

12. Received pursuant to the Merger Agreement in exchange for an identical number of performance share units payable in Eclipsys Corporation common stock.

	/s/ Kathie Kittner by power of attorney for John Gomez	08/26/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.